A phase III study comparing adjuvant chemotherapy consisting of capecitabine/oxaliplatin vs surgery alone in patients with stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) gastric adenocarcinoma.

Trial Profile

A phase III study comparing adjuvant chemotherapy consisting of capecitabine/oxaliplatin vs surgery alone in patients with stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) gastric adenocarcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CLASSIC
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 20 Nov 2015 According to Chugai Pharmaceuticals media release, company announced that it has obtained supplemental approval from the Japanese Ministry of Health, Labour and Welfare (MHLW).
    • 20 Nov 2015 Results published in Chugai Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top